Treatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic
Highlights
- • During the COVID-19 pandemic, management of STSTEMI is challenging.
- • Many patients have a contraindication to thrombolysis and end up using resources with this treatment.
- • There is a high probability that an infected patient will show a normal angiogram.
- • Primary PCI should be the preferred strategy in STEMI patients, with precautions.
Abstract
The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. In this review, we outline the risks and benefits of primary PCI vs. thrombolysis for STEMI. While thrombolysis may seem like a good choice, many patients have a contraindication and could end up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy.